Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 122.19% | 236.18% | 627.11% | 403.88% | 207.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.19% | 236.18% | 627.11% | 403.88% | 207.76% |
| Cost of Revenue | 108.54% | 186.05% | 346.22% | 231.63% | 116.57% |
| Gross Profit | 132.78% | 285.72% | 1,320.32% | 743.91% | 357.24% |
| SG&A Expenses | 76.63% | 94.22% | 110.06% | 18.32% | -34.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.06% | 124.12% | 167.95% | 58.53% | -11.23% |
| Operating Income | 71.22% | 61.65% | 58.93% | 72.41% | 80.02% |
| Income Before Tax | -74.98% | -44.60% | -26.82% | 27.89% | 65.72% |
| Income Tax Expenses | -177.39% | 10.45% | 35.96% | -177.46% | -106.36% |
| Earnings from Continuing Operations | -68.72% | -55.71% | -44.94% | 40.34% | 75.35% |
| Earnings from Discontinued Operations | -368,795.00% | -104.19% | -101.36% | -100.77% | -100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.72% | -238.10% | -158.78% | -171.58% | -262.38% |
| EBIT | 71.22% | 61.65% | 58.93% | 72.41% | 80.02% |
| EBITDA | 1,124.40% | 186.31% | 125.54% | 107.40% | 96.11% |
| EPS Basic | -161.94% | -139.55% | -130.77% | -94.00% | 373.59% |
| Normalized Basic EPS | 45.54% | 42.69% | 42.54% | 61.68% | 73.43% |
| EPS Diluted | -162.02% | -139.59% | -130.80% | -94.02% | 377.75% |
| Normalized Diluted EPS | 45.54% | 42.69% | 42.54% | 61.68% | 73.43% |
| Average Basic Shares Outstanding | 30.08% | 29.51% | 28.96% | 29.67% | -26.73% |
| Average Diluted Shares Outstanding | -2.87% | -3.09% | -3.30% | -2.65% | -1.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |